01 June 2005 : Case report
The additive effects of carnitine and ascorbic acid on distally burned dorsal skin flap in rats
Emrah Arslan, Yavuz Basterzi, Alper Aksoy, Christopher Majka, Sakir Unal, Alper Sari, Ferit DemirkanMed Sci Monit 2005; 11(6): BR176-180 :: ID: 16488
Abstract
Summary
Background: The purpose of this study was to determine the effects of combined use of L-carnitine and vitamin C on partially burned skin fl ap in an experimental rat model.
Material/Methods: In the rat dorsal skin, a 10×3 cm fl ap was marked. The most distal 3×3 cm part was burned to full thickness. Twenty-four rats were randomized into four groups with 6 animals in each. Group 1 was simply followed up. Group 2 was given 0.5 mg/kg vitamin C per day for 7 days, group 3 100 mg/kg carnitine per day for 7 days, and group 4 both carnitine and vitamin C. On the eighth postoperative
day, the animals were sacrifi ced and examined. The surviving and necrotic areas were determined by macroscopic examination and measured with a planimeter.
Results: The areas of fl ap necrosis were measured. The median surviving areas and areas of fl ap necrosis, respectively, of the groups were: group 1, 16.0 cm2 and 14.0 cm2; group 2, 18.25 cm2 and 11.75 cm2; group 3, 20.0 cm2 and 10 cm2; and group 4, 23.75 cm2 and 6.25 cm2. The surviving areas of the groups were found to be signifi cantly different (p=0.000).
Conclusions: The risk of ischemia-induced necrosis in fl ap attempts made in damaged tissues may be reduced by the combination of two promising agents, L-carnitine and vitamin C. L-carnitine appears to be
the major contributing factor that reduces necrosis, and vitamin C an additive agent.
Keywords: Ascorbic Acid - therapeutic use, Carnitine - therapeutic use, Antioxidants - therapeutic use, Ascorbic Acid - therapeutic use, Burns - drug therapy, Carnitine - therapeutic use, Skin - pathology, Surgical Flaps
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952